You just read:

Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

News provided by

MEI Pharma, Inc.

Jun 14, 2017, 08:30 ET